Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Timber Hill LLC v. Pershing Square Capital Management, L.P. et al
Case Number:
2:17-cv-04776
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
- Bausch Health Cos. Inc.
- Pershing Square Capital Management LP
- State Teachers Retirement System of Ohio
- Two Sigma Investments LP
Sectors & Industries:
-
March 19, 2018
Valeant, Pershing Get Initial OK On $290M Investor Deals
A California federal judge granted preliminary approval Monday to two settlements totaling $290 million from Pershing Square Capital Management LP and Valeant Pharmaceuticals International Inc. to resolve investor claims of an insider-trading scheme ahead of their failed takeover bid for Allergan Inc.
-
January 02, 2018
Pershing, Valeant Agree To $290M Deal Ending Allergan Suits
Hedge fund Pershing Square and Valeant Pharmaceuticals have reached a $290 million preliminary agreement to settle two investor suits in California federal court accusing them of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan.
-
November 07, 2017
Investors Spar Over Damages In Valeant, Pershing Rows
Investors behind two suits accusing Valeant Pharmaceuticals and hedge fund Pershing Square of an insider trading scheme in connection with Valeant's attempted $55 billion takeover of Allergan Inc. duked it out in California federal court Monday over proposals for how to handle potentially competing damages awards in their respective cases.
-
October 13, 2017
Susman, Entwistle To Lead Valeant Insider Trading Suit
Entwistle & Cappucci LLP and Susman Godfrey LLP on Friday nabbed the co-lead counsel spots in a consolidated proposed class action alleging Valeant Pharmaceuticals and billionaire investor Bill Ackman's hedge fund engaged in an insider trading scheme that cost derivatives investors billions.
-
August 30, 2017
Susman Godfrey Seeks To Helm Valeant Insider Trading Suit
Susman Godfrey LLP and Entwistle & Cappucci LLP urged a California federal judge Tuesday to appoint them co-lead counsel for a proposed class action alleging Valeant Pharmaceuticals and Bill Ackman's hedge fund engaged in an insider trading scheme that cost derivatives investors billions.